Resistance of naive mice to murine hepatitis virus strain 3 requires development of a Th1, but not a Th2, response, whereas pre-existing antibody partially protects against primary infection

Journal of Immunology

Volumn 156, Issue 9, 1996, Pages 3342-3349

  Pope, Marc ^a   Chung, Stephen W ^a   Mosmann, Tim ^b   Leibowitz, Julian L ^c   Gorczynski, Reginald M ^a   Levy, Gary A ^a,d  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF TEXAS   (United States)

^d NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; PROCOAGULANT; VIRUS ANTIBODY;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HELPER CELL; IMMUNIZATION; INFECTION RESISTANCE; MOUSE; MURINE HEPATITIS CORONAVIRUS; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; VIRUS ATTENUATION; VIRUS STRAIN;

ANIMALS; ANTIBODIES, VIRAL; BLOOD COAGULATION FACTORS; CELL LINE; CORONAVIRUS INFECTIONS; DISEASE SUSCEPTIBILITY; FEMALE; HEPATITIS, VIRAL, ANIMAL; IMMUNITY, NATURAL; IMMUNIZATION, PASSIVE; IMMUNOTHERAPY, ADOPTIVE; MACROPHAGES; MICE; MICE, INBRED A; MICE, INBRED BALB C; MICE, INBRED C57BL; MURINE HEPATITIS VIRUS; SPLEEN; TH1 CELLS; TH2 CELLS; VIRAL VACCINES;

EID: 0029886524     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Lee, W. J. 1993. Acute liver failure. N. Engl. J. Med. 329:1862.
2. Spaan, W., D. Cavanagh, and M. Horzinek. 1990. Coronaviruses. In Immunochemistry of Viruses. II. The Basis for Serodiagnosis and Vaccines, M. H. V. Van Regenmortel and A. R. Neurath, eds. Elsevier Science Publishers, Amsterdam, p. 359.
3. MacPhee, P. J., V. J. Dindzans, L. S. Fung, and G. A. Levy. 1985. Acute and chronic changes in the microcirculation of the liver in inbred strains of mice following infection with mouse hepatitis virus type 3. Hepatology 5:649.
4. Levy, G. A., J. L. Leibowitz, and T. S. Edgington. 1981. Induction of menocyte procoagulant activity by murine hepatitis virus type 3 parallels disease susceptibility in mice. J. Exp. Med. 154:1150.
5. MacNaughton, M. R., and S. Patterson. 1980. Mouse hepatitis virus strain 3 infection of C57,A/Sn and A/J strain mice and their macrophages. Arch. Virol. 66:71.
6. Li, C., L. S. Fung, A. Crow, N. Myers-Mason, J. L. Leibowitz, E. Cole, and G. A. Levy. 1992. Monoclonal anti-prothrombinase (3D4.3) prevents mortality from murine hepatitis virus infection (MHV-3). J. Exp. Med. 1763:689.
7. Parr, R., J. L. Leibowitz, L. S. Fung, S. J. Reneker, N. Myers-Mason, and G. A. Levy. 1995. The association of mouse fibrinogen-like protein (Musfiblp) with murine hepatitis virus induced prothrombinase activity. J. Virol. 69:5033.
8. Qureshie, S. T., S. Clermont, J. Leibowitz, L. S. Fung, G. A. Levy, and D. Malo. 1995. Murine hepatitis virus-3 induced prothrombinase (Musfiblp) maps to proximal chromosome 5. Genomics 29:307.
9. Mosmann, T. R., and R. L. Coffman. 1989. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:145.
10. Heinzel, F. P., M. D. Sadick, B. J. Holaday, R. L. Coffman, and R. M. Locksley. 1989. Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis: evidence for expansion of distinct helper T cell subsets. J. Exp. Med. 169:59.
11. Sypek, J. P., C. L. Chung, S. H. Mayor, J. M. Subramanyam, S. J. Goldman, D. S. Sieburth, S. F. Wolf, and R. G. Schaub. 1993. Resolution of cutaneous leishmaniasis: interleukin-12 initiates a protective T helper type 1 immune response. J. Exp. Med. 177:1797.
12. Scott, P. 1991. IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis. J. Immunol. 147:3149.
13. Gajewski, T., and F. W. Fitch. 1988. Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. J. Immunol. 140:4245.
14. Belosevic, M., D. S. Finbloom, P. H. Van der Meide, M. V. Slayter, and C. Nacy. 1989. Administration of monoclonal anti-IFN-gamma antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major. J. Immunol. 143:266.
15. Swain, S., A. D. Weinberg, M. English, and G. Huston. 1990. IL-4 directs the development of Th2-like helper effectors. J. Immunol. 145:3796.
16. Chatelain, R., K. Varkila, and R. L. Coffman. 1992. IL-4 induces a Th2 response in Leishmania major-infected mice. J. Immunol. 148:11827.
17. Fiorentino, D. F., A. Zlotnik, P. Vieira, T. R. Mosmann, M. Howard, K. W. Moore, and A. O'Garra. 1991. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J. Immunol. 146:3444.
18. Romani, L., S. Mocci, C. Bietta, L. Lanfaloni, P. Puccetti, and F. Bistoni. 1991. Th1 and Th2 cytokine secretion patterns in murine candidiasis: association of Th1 responses with acquired resistance. Infect. Immun. 59:4647.
19. Cenci, E., L. Romani, A. Vecchiarelli, P. Puccetti, and F. Bistoni. 1990. T cell subsets and IFN-gamma production in resistance to systemic candidosis in immunized mice. J. Immunol. 144:4333.
20. Haak-Frendscho, M., J. F. Brown, Y. Iizawa, D. R. Wagner, and C. J. Czuprynski. 1992. Administration of anti-IL-4 monoclonal antibody 11B11 increases the resistance of mice to Listeria monocytogenes infection. J. Immunol. 148:3978.
21. Liew, F. Y., S. Millott, Y. Li, R. Lelchuk, W. L. Chan, and H. Ziltener. 1989. Macrophage activation by interferon-gamma from host-protective T cells is inhibited by interleukin (IL) 3 and IL-4 produced by disease-promoting T cells in leishmaniasis. Eur. J. Immunol. 19:1227.
22. Romani, L., A. Mencacci, U. Grohmann, S. Mocci, P. Mosci, P. Puccetti, and F. Bistoni. 1992. Neutralizing antibody to interleukin 4 induces systemic protection and T helper type 1-associated immunity in murine candidiasis. J. Exp. Med. 176:19.
23. Sadick, M. D., F. P. Heinzel, B. J. Holaday, R. T. Pu, R. S. Dawkins, and R. M. Locksley. 1990. Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody: evidence for a T cell-dependent, interferon gamma-independent mechanism. J. Exp. Med. 171:115.
24. Romagnani, S. 1991. Human Th1 and Th2 subsets: doubt no more. Immunol. Today 12:256.
25. Modlin, R. L., and T. B. Nutman. 1993. Type 2 cytokines and negative immune regulation in human infections. Curr. Opin. Immunol. 5:511.
26. Chung, S., S. Sinclair, J. Leibowitz, E. Skamene, L. S. Fung, and G. Levy. 1991. Cellular and metabolic requirements for induction of macrophage procoagulant activity by murine hepatitis virus strain 3 in vitro. J. Immunol. 146:271.
27. Levy, G. A., and T. S. Edgington. 1980. Lymphocyte cooperation is required for amplification of macrophage procoagulant activity. J. Exp. Med. 151:1232.
28. + T helper cell subsets that induce the monocyte procoagulant response. Cell. Immunol. 128:52.
29. Chung, S., R. Gorczynski, B. Cruz, R. Fingerote, E. Skamene, S. Perlman, J. L. Leibowitz, L. S. Fung, M. Flowers, and G. A. Levy. 1994. A TH1 helper cell line (3E9.1) from resistant A/J mice inhibits induction of macrophage procoagulant activity (PCA) in vitro and protects against MHV-3 mortality in vivo. Immunology 83:353.
30. Dindzans, V. J., B. Zimmerman, A. Sherker, and G. A. Levy. 1987. Susceptibility to mouse hepatitis virus strain 3 in BALB/cJ mice: failure of immune cell proliferation and interleukin 2 production. Adv. Exp. Med. Biol. 218:411.
31. Lamontagne, L., and P. Jolicoeur. 1991. Mouse hepatitis virus 3-thymic cell interactions correlating with viral pathogenecity. J. Immunol. 146:3152.
32. Nesbitt, M. N., and E. Skamene. 1984. Recombinant inbred mouse strains derived from A/J and C57BL/6J: a tool for the study of genetic mechanisms in host resistance to infection and malignancy. J. Leukocyte Biol. 36:357.
33. Dindzans, V. J., P. J. MacPhee, L. S. Fung, I. L. Leibowitz, and G. A. Levy. 1985. The immune response to mouse hepatitis virus: expression of monocyte procoagulant activity and plasminogen activator during infection in vivo. J. Immunol. 135:4189.
34. Levy, G. A., R. Shaw, J. L. Leibowitz, and E. Cole. 1984. The immune response to mouse hepatitis virus: genetic variation in antibody response and disease. Adv. Exp. Med. Biol. 173:345.
35. Gillis, S., M. M. Fern, W. Ou, and K. A. Smith. 1978. T cell growth factor: parameters of production and a quantitative microassay for activity. J. Immunol. 120:2027.
36. Vilcek, J., and I. C. Oliveira. 1994. Recent progress in the elucidation of interferon-gamma actions: molecular biology and biological functions. Int. Arch. Allergy Immunol. 104:311.
37. Le Prevost, C., E. Levy-Leblond, J. L. Virelizier, and J. M. Dupuy. 1975. Immunopathology of mouse hepatitis virus type 3 infection. I. Role of humoral and cell-mediated immunity in resistance mechanisms. J. Immunol. 114:221.
38. Dupuy, J. M., E. Levy-Leblond, and C. Le Prevost. 1975. Immunopathology of mouse hepatitis virus type 3 infection. II. Effect of immunosuppression in resistant mice. J. Immunol. 114:226.
39. Levy-Leblond, E., and J. M. Dupuy. 1977. Neonatal susceptibility to MHV-3 infection in mice. I. Transfer of resistance. J. Immunol. 118:1219.
40. + cells. J. Immunol. 147:2317.
41. Stohlman, S. A., G. K. Matsushima, N. Casteel, and L. P. Weiner. 1986. In vivo effects of coronavirus-specific T cell clones: DTH inducer cells prevent a lethal infection but do not inhibit virus replication. J. Immunol. 136:3052.
42. Lamontagne, L., J. P. Descoteaux, and P. Jolicoeur. 1989. Mouse hepatitis virus 3 replication in T and B lymphocytes correlate with viral pathogenicity. J. Immunol. 142:4458.
43. Virelizier, J. L., and I. Gressor. 1978. Role of interferon in the pathogenesis of viral disease in mice as demonstrated by the use of anti-interferon serum. V. Protective role in mouse hepatitis virus type 3 infection of susceptible and resistant strains of mice. J. Immunol. 120:1616.
44. Stohlman, S., C. Bergmann, D. Cua, H. Wege, and R. Van der Veen. 1994. Location of antibody epitopes within the mouse hepatitis virus nucleocapsid protein. Virology 202:146.
45. Mougneau, E., F. Altare, A. E. Wakil, S. Zheng, T. Coppola, Z. Wang, R. Waldmann, R. M. Locksley, and N. Glaichenhaus. 1995. Expression cloning of a protective Leishmania antigen. Science 268:563.
46. Bretscher, P. A., G. Wei, J. N. Menon, and H. Bielefeldt-Ohmann. 1992. Establishment of stable, cell-mediated immunity that makes "susceptible" mice resistant to Leishmania major. Science 257:539.
47. Corry, D. B., S. L. Reiner, P. S. Linsley, and R. M. Locksley. 1994. Differential effects of blockade of CD28-B7 on the development of Th1 or Th2 effector cells in experimental leishmaniasis. J. Immunol. 153:4142.
48. Hsieh, C., S. E. Macatonia, A. O'Garra, and K. M. Murphy. 1995. T cell genetic background determines default T helper phenotype development in vitro. J. Exp. Med. 181:713.